New combo aims to save bladders in cancer fight
NCT ID NCT07201675
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two drugs, Vedisertib and Toripalimab, can shrink muscle-invasive bladder cancer so patients can keep their bladder. About 59 adults with early-stage cancer will receive the drugs in cycles, with regular checks to see if the cancer disappears. If it does, they continue on maintenance therapy for a year; if not, they leave the study for other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CANCER (MIBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could spot bladder Cancer's return
- Bladder preservation: a viable alternative to radical surgery?
- New drug duo aims to wipe out bladder tumors before surgery
- New bladder cancer combo shows promise in Pre-Surgery trial
- Promising combo aims to shrink bladder tumors before surgery
- Which scan is better for bladder cancer staging? new study aims to find out